

hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents, Washington, D.C. 20231, April 10, 2001

The Law Offices of Jonathan Alan Quine

Attorney Docket No. 02-102320US Client Ref. No. 0154.003

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Juha Punnonen, et al.

Application No.: 09/760,388

Filed: January 10, 2001

For: MONOCYTE-DERIVED DENDRITIC CELL SUBSETS Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR § 1.97 and

§ 1.98

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Application No.: 09/760388

Page 2

Applicant believes that <u>no fee is required</u> for submission of this statement, since is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Gwynedd Warren Reg. No. 45,200

THE LAW OFFICES OF JONATHAN ALAN QUINE

P.O. Box 458

Alameda, CA 94501 Tel: (510) 337-7871 Fax: (510) 337-7877

GW:afa

Substitute for form 1449A-B/PTO	C	omplete if Known
	Application Number	09/760388
NFORMATION DISCLOSURE	Filing Date	January 10, 2001
STATEMENT BY APPLICANT	First Named Inventor	Juha Punnonen
ATEMENT BY APPLICANT	Group Art Unit	Unassigned
	Examiner Name	Unassigned
e as many sheets as necessary)	Attorney Docket Number	02-102320US

RADEMARI Examiner	/ — — —	U.S. Patent Docum		S. PATENT DOCUMENT		Pages, Columns, lines,
Examiner Initials	Cite No.	Number	Kind Code (if known)	Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appea
	AA	5,512,463		Stemmer	04-30-1996	
	AB	5,514,588		Varadaraj	05-07-1996	
	AC	5,605,793		Stemmer	02-25-1997	
	AD	5,763,239		Short et al.	06-09-1998	
	ΑE	5,789,228		Lam et al.	08-04-1998	
	AF	5,811,238		Stemmer et al.	09-22-1998	
	AG	5,814,473		Warren et al.	09-29-1998	
	АН	5,824,469		Horwitz et al.	10-20-1998	
	Al	5,830,696		Short	11-03-1998	
	AJ	5,830,721		Stemmer et al.	11-03-1998	
	AK	5,834,252		Stemmer et al.	11-10-1998	
•	AL	5,837,458		Minushull et al.	11-17-1998	
	AM	5,866,363		Pieczenik	02-02-1999	
	AN	5,876,997		Kretz	03-02-1999	
	AO	5,925,749		Mathur, et al.	07-20-1999	
	AP	5,928,905		Stemmer, et al.	07-27-1999	
	AQ	5,939,250		Short, Jay M.	08-17-1999	
	AR	5,939,300		Robertson, et al.	08-17-1999	
	AS	5,942,430		Robertson, et al.	08-24-1999	
	AT	5,948,666		Callen, et al.	09-07-1999	
	AU	5,958,672		Short, Jay M.	09-28-1999	
	AV	5,958,751		Murphy, et al.	09-28-1999	
	AW	5,962,258		Mathur, et al.	10-05-1999	
	AX	5,962,283		Warren et al.	10-05-1999	
	AY	5,965,408		Short, Jay M.	10-12-1999	
	AZ	5,985,646		Murphy, et al.	11-16-1999	
	BA	5,994,126		Steinman et al.	11-30-1999	
xamine Signatur					Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	C	omplete if Known	
	Application Number	09/760388	
JINFORMATION DISCLOSURE	Filing Date	January 10, 2001	
ENFORMATION DISCLOSURE STAREMENT BY APPLICANT	First Named Inventor	Juha Punnonen	
<b>3</b> /	Group Art Unit	Unassigned	
1 3 201 3 (use many sheets as necessary)	Examiner Name	Unassigned	
(usassary)	Attorney Docket Number	02-102320US	

N IN	1			
W & TRADE BB	6,001,574	Short et al.	12-14-1999	
BC	6,004,788	Short	12-21-1999	
BD	6,030,779	Short	02-29-2000	
BE	6,054,267	Short	04-25-2000	
BF	6,057,103	Short	05-02-2000	
BG	6,096,548	Stemmer	08-01-2000	
ВН	6,117,679	Stemmer	09-12-2000	
BI	6,132,970	Stemmer	10-17-2000	
BJ	6,165,793	Stemmer	12-26-2000	
BK	6,168,919	Short	01-02-2001	
BL	6,171,820	Short	01-09-2001	
ВМ	6,174,673	Short, et al.	01-16-2001	
BN	6,180,406	Stemmer	01-30-2001	

				FOREIGI	N PATENT DOCUMEN	TS		
Examin er Initials	Cite No.	Office	Foreign Patent Docur Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
	во	wo	94/02156		The Board of Trustees of Leland Stanford Junior University	02-03-1994		
	BP	wo	97/07205		Novo Nordisk A/S	02-27-1997		
	BQ	wo	97/20078		Affymax Technologies	06-05-1997		
	BR	wo	97/24447		Chiron Viagene, Inc.	07-10-1997		
	BS	wo	97/25410		Novo Nordisk A/S	07-17-1997		
	ВТ	wo	97/29182		The Rockefeller University	08-14-1997		
	BU	wo	97/29183		US Dept. of Health and Human Services	08-14-1997		
	BV	wo	97/35957		Maxygen, Inc.	10-02-1997		
	BW	wo	97/35966		Maxygen, Inc.	10-02-1997		
	вх	wo	97/44361		Recombinant	11-27-1997		

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	С	Complete if Known		
	Application Number	09/760388		
INFORMATION DISCLOSURE	Filing Date	January 10, 2001		
STATEMENT BY APPLICANT	First Named Inventor	Juha Punnonen		
TATEMENT BY APPLICANT	Group Art Unit	Unassigned		
	Examiner Name	Unassigned		
as many sheets as necessary)	Attorney Docket Number	02-102320US		

3 0		T	<del></del>	Biocatalysis Inc.	T	1
RADEM	BY	wo	97/48416	Recombinant	12-24-1997	
				Biocatalysis, Inc.		
	BZ	WO	97/48717	Recombinant Biocatalysis Inc	12-24-1997	
	CA	wo	97/48794	Recombinant Biocatalysis Inc	12-24-1997	
	СВ	wo	98/00526	Recombinant Biocatalysis Inc	01-08-1998	
	СС	wo	98/01581	Recombinant Biocatalysis Inc	01-15-1998	
	CE	wo	98/05795	The Center for Blood Research, Inc	02-12-1998	
	CD	wo	98/13485	Maxygen, Inc.	04-02-1998	
	CF	wo	98/13487	Maxygen, Inc.	04-02-1998	
	CG	wo	98/24799	Diversa Corp.	06-11-1998	
	СН	wo	98/27230	Maxygen, Inc.	06-25-1998	
	CI	wo	98/28416	Novo Nordisk A/S	07-02-1998	
	CJ	wo	98/31837	Maxygen, Inc.	07-23-1998	
	СК	wo	98/36080	Maxygen, Inc.	08-20-1998	
	CL	wo	98/41622	Novo Nordisk A/S	09-24-1998	
	СМ	wo	98/41623	Novo Nordisk A/S	09-24-1998	
	CN	wo	98/41653	Novo Nordisk A/S	09-24-1998	
	СО	wo	98/42832	California Institute of Technology	10-01-1998	
	СР	wo	98/48034	Diversa Corp.	10-29-1998	
	CQ	wo	98/53048	US Dept. of Health and Human Services	11-26-1998	
	CR	wo	98/58085	Diversa Corp.	12-23-1998	
	cs	wo	99/00137	Hemosol Inc.	05-27-1999	
	СТ	wo	99/07837	Diversa Corp.	02-19-1999	
	CU	wo	99/08539	Diversa Corp.	02-25-1999	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sul	Substitute for form 1449A-B/PTO				Complete if K	nown		
					Application Number	09/760388		
			ISCLOSURE		Filing Date	January 1		
EST	ATEME	ENT BY	APPLICANT		First Named Inventor	Juha Pun		
JAE .	Cie				Group Art Unit	Unassign		
	A IS PAR	many she	ets as necessary)		Examiner Name	Unassign		
لجها					Attorney Docket Num	ber 02-102320	JUS	
133		14/0	00/10470		Diversa Corp.	03-04-1999		T
ENT & TR	C.	wo	99/10472					├—
18 18	CW	WO	99/10539		Diversa Corp.	03-04-1999		-
	СХ	wo	99/19518		Diversa Corp.	04-22-1999		┝
	CY	EP	0911396A2		Maxygen, Inc.	04-28-1999		<u> </u>
	CZ	wo	99/21979		Maxygen, Inc.	05-06-1999	)	<u> </u>
	DA	EP	0911396A3		Maxygen, Inc.	05-06-1999		<u> </u>
	DB	wo	99/23107		Maxygen, Inc.	05-14-1999		
	DC	wo	99/23236		Diversa Corp.	05-14-1999		
	DD	wo	99/25812		Hemosol Inc.	05-27-1999	)	
	DE	EP	0934999A1		Maxygen, Inc.	08-11-1999	)	<u> </u>
	DF	wo	99/41368		Maxygen, Inc.	08-19-1999		
	DG	wo	99/41369	,	Maxygen, Inc.	08-19-1999		
	DH	wo	99/41383		Maxygen, Inc.	08-19-1999	<u> </u>	
	DI	wo	99/41402		Maxygen, Inc.	08-19-1999	)	
	DJ	wo	99/45154		Diversa Corp.	09-10-1999	<u> </u>	
	DK	wo	99/57128		Maxygen, Inc.	11-11-1999	)	_
	DL	wo	99/65927		Maxygen, Inc,	12-23-1999	)	
	DM	wo	00/42560		Maxygen, Inc.	07-20-2000	)	
	DN	wo	00/42561		Maxygen, Inc.	07-20-2000		
	DO	wo	00/53744		Diversa Corporatio	on 09-14-2000		
	DP	wo	00/58517		Diversa Corporatio			
	,		OTHER PRIOR	ART -	NON PATENT LITERA	ATURE DOCUM	ENTS	· · ·
Examin er Initials	Cite No.	se	rial, symposium, catalog	g, etc.), da	te, page(s), volume-issue numbe	r(s), publisher, city and		Т
	DQ	Blom, B., et al., "Generation of Interferon α-producing Predendritic Cell (Pre-DC) <sup>2</sup> from Human DC34 <sup>+</sup> Hematopoietic Stem Cells," <i>J. Exp. Med.</i> , 192(12):1785-1795 (December 18, 2000)						
	DR	Their C	ytokine Producti	ion Pro	te-Derived CD1a <sup>+</sup> and tiles, Susceptibilities to burnal of Immunology, 2	Transfection, ar	nd Capacities to Direct	
	DS		, C., et al. (1999) hnology 17:793-7		ition of a cytokine using	DNA family shu	ıffling." <u>Nature</u>	
Exami	ner			·		Date		
Signati	ure					Considered		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Co	omplete if Known	
Application Number	09/760388	
Filing Date	January 10, 2001	
First Named Inventor	Juha Punnonen	
Group Art Unit	Unassigned	
Examiner Name	Unassigned	
Attorney Docket Number	02-102320US	

(use as many sheets as necessary)

	DT	Christians, F.C. et al., (1999) "Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling." <i>Nature Biotechnology</i> 17:259-264.	
	DU	Crameri et al., (1993) "10(20)-Fold aptamer library amplification without gel purification," Nuc. Acids Res. 21(18):4410.	
	DV	Crameri, A. & Stemmer W.P.C. (1995) "Combinatorial multiple cassette mutagenesis creates all the permutations of mutant and wildtype cassettes." <i>Biotechniques</i> 18:194-195.	L
	DW	Crameri, A. et al. (1996) "Improved green fluorescent protein by molecular evolution using DNA shuffling." <i>Nature Biotechnology</i> 14:315-319.	<u> </u>
	DX	Crameri, A. et al. (1996) "Construction and evolution of antibody-phage libraries by DNA shuffling." <i>Nature Medicine</i> 2:100-103.	L
	DY	Crameri, A. et al., (1997) "Molecular evolution of an arsenate detoxification pathway by DNA shuffling." Nature Biotechnology 15:436-438	
	DZ	Crameri, A. et al., (1998) "DNA shuffling of a family of genes from diverse species accelerates directed evolution." <i>Nature</i> 391:288-291.	
	EA	Gates, C.M. et al., (1996) "Affinity selective isolation of ligands from peptide libraries through display on a lac repressor 'headpiece dimer'". <u>Journal of Molecular Biology</u> 255:373-386.	
	EB	Minshull, J., Stemmer, W.P.C. (1999) "Protein evolution by molecular breeding." <u>Current Opinion in Chemical Biology</u> 3:284-290.	
	EC	Ness, J. et al., (1999) "DNA shuffling of subgenominc sequences of subtilisin." <u>Nature</u> <u>Biotechnology</u> 17:893-896.	
	ED	Nestle, F.O., et al., "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells," <i>Nature Medicine</i> , 4(3):328-332 (March 1998)	
	EE	Patten, P.A. et al., (1997) "Application of DNA Shuffling to Pharmaceuticals and Vaccines." <u>Current Opinion in Biotechnology</u> 8:724-733.	
	EF	Spits, H., et al., "Id2 and Id3 Inhibit Development of CD34 <sup>+</sup> Stem Cells into Predendritic Cell (Pre-DC) <sup>2</sup> but Not into Pre-DE1: Evidence for a Lymphoid Origin of Pre-DC2," <i>J. Exp. Med.</i> , 192(12):1775-1783 (December 18, 2000)	
	EG	Stemmer, W.P.C. (1994) "DNA Shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution." <i>PNAS</i> 91:10751	
	EH	Stemmer, W.P.C. (1994) "Rapid evolution of a protein in vitro by DNA shuffling." <i>Nature</i> 370:389-391.	
	EI	Stemmer, W.P.C. (1995) "The Evolution of Molecular Computation." Science 270:1510	
-	EJ	Stemmer, W.P.C. (1995) "Searching Sequence Space." Bio/Technology 13:549-553.	
	EK	Stemmer, W.P.C. (1996) "Sexual PCR and Assembly PCR." In: <u>The Encyclopedia of Molecular Biology</u> . VCH Publishers, New York. pp. 447-457.	

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute from 1449A-B/PAP INFORMATION DISCLOSURE STATEMENT BY APPLICANT

C	omplete if Known	
Application Number	09/760388	
Filing Date	January 10, 2001	
First Named Inventor	Juha Punnonen	
Group Art Unit	Unassigned	
Examiner Name	Unassigned	
Attorney Docket Number	02-102320US	

(use as many sheets as necessary)

E	EL	Stemmer, W.P.C. & Soong, N.W. (1999) "Molecular breeding of viruses for targeting and other clinical properties." <i>Tumor Targeting</i> 4:59-62.
E	EM	Timmerman, J. M., et al., "Dendritic Cell Vaccines for Cancer Immunotherapy," <i>Annu. Rev. Med.</i> 1999, 50:507-529
E	EN	Yssel, H., et al., "Serum-Free Medium for Generation and Propagation of Functional Human Cytotoxic and Helper T Cell Clones," <i>J. Immunol. Methods</i> , 72(1):219-277 (1984)
E	EO	Zhang, J. et al., (1997) "Directed evolution of an effective fucosidase from a galactosidase by DNA shuffling and screening." <i>Proceedings of the National Academy of Sciences, USA</i> 94:4504-4509.

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.